← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,646	+331	+10%	$311B
2	2 Pfizer PFE $168B	3,263	+457	+16%	$224B
3	3 AbbVie ABBV $501B	2,982	+325	+12%	$162B
4	4 Merck MRK $358B	2,903	+254	+10%	$142B
5	5 Bristol-Myers Squibb BMY $124B	2,445	+151	+7%	$100B
6	6 Amgen AMGN $235B	2,293	+159	+7%	$95.5B
7	7 Gilead Sciences GILD $195B	1,681	+117	+7%	$73.6B
8	8 Novartis NVS $286B	1,146	+65	+6%	$18.5B
9	9 Regeneron Pharmaceuticals REGN $82B	1,078	+59	+6%	$56.9B
10	10 AstraZeneca AZN $259B	950	+41	+5%	$29.4B
11	11 GSK GSK $98.2B	919	+126	+16%	$14.5B
12	12 DELISTED Exact Sciences EXAS	596	-6	-1%	$12.5B
13	13 Incyte INCY $23B	526	+32	+6%	$14.9B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	525	+42	+9%	$25.5B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	454	-1	-0.2%	$7.37B
16	16 Guardant Health GH $22.3B	396	+22	+6%	$9.24B
17	17 BioNTech BNTX $22.7B	354	+18	+5%	$9.07B
18	18 Natera NTRA $58.3B	331	-19	-5%	$8.61B
19	19 Exelixis EXEL $15.6B	329	-11	-3%	$4.89B
20	20 Halozyme HALO $13.8B	325	0	0%	$5.2B
21	21 NeoGenomics NEO $2.22B	307	-17	-5%	$4.02B
22	22 Qiagen QGEN $9.53B	301	+36	+14%	$7.53B
23	23 Takeda Pharmaceutical TAK $62.1B	299	+6	+2%	$1.04B
24	24 DELISTED Blueprint Medicines BPMC	280	-8	-3%	$6.32B
25	25 BeOne Medicines Ltd ONC $42.3B	263	+9	+4%	$15B